{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "EMA EPAR|DISEASES" in comments (approximate match)
Status:
Possibly Marketed Outside US
Source:
NCT03449342: Phase 4 Interventional Completed Congenital Bleeding Disorder
(2018)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT00514813: Phase 4 Interventional Terminated Anemia
(2007)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT00172809: Phase 4 Interventional Completed Chronic Hepatitis C
(2005)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT00161616: Phase 4 Interventional Completed Tibial Fractures
(2003)
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2015)
First approved in 2015
Class:
NUCLEIC ACID
